For its third fiscal quarter (ending September 30), Biomarin Pharmaceutical Inc (NASDAQ: BMRN) has reported a 167% increase in E.P.S. from $0.21 a year ago to $0.56 in the current quarter. E.P.S. were $1.70 for the latest four quarters through September 30 versus $0.78 for the same period a year ago — an increase of 118%.
Recent Price Action
Biomarin Pharmaceutical Inc (NASDAQ: BMRN) stock declined slightly by -0.3% on 10/29/24. The stock closed at $69.91. NORMAL trading volume accompanied the decline. The stock has been weak relative to the market over the last nine months and has declined -0.5% during the last week.
Current PriceTarget Research Rating
BMRN’s future returns on capital are forecasted to exceed the cost of capital. Accordingly, the company is expected to continue to be an important Value Builder.
Biomarin Pharmaceutical has a current Value Trend Rating of C (Low Neutral). The Value Trend Rating reflects consistent signals from PTR’s two proprietary measures of a stock’s attractiveness. Biomarin Pharmaceutical has a neutral Appreciation Score of 50 and a slightly negative Power Rating of 39, leading to the Low Neutral Value Trend Rating.
Rating Review
In light of this new information we are reviewing our current Overall Rating of C. This review will be completed in the next several days.
Be the first to comment